GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhaseRx Inc (OTCPK:PZRXQ) » Definitions » Total Payout Yield %

PhaseRx (PhaseRx) Total Payout Yield % : 0.00 (As of Jun. 05, 2024)


View and export this data going back to 2016. Start your Free Trial

What is PhaseRx Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

PhaseRx's current Total Payout Yield % is 0.00%.


PhaseRx Total Payout Yield % Historical Data

The historical data trend for PhaseRx's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhaseRx Total Payout Yield % Chart

PhaseRx Annual Data
Trend Dec14 Dec15 Dec16
Total Payout Yield %
- - -90.92

PhaseRx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Total Payout Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PhaseRx's Total Payout Yield %

For the Biotechnology subindustry, PhaseRx's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PhaseRx's Total Payout Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhaseRx's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where PhaseRx's Total Payout Yield % falls into.



PhaseRx Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

PhaseRx's Total Payout Yield % for the fiscal year that ended in Dec. 2016 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Market Cap
=- (0 + 16.475 + 0) / 18.119965
=-90.92%

PhaseRx's annualized Total Payout Yield % for the quarter that ended in Sep. 2017 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) * Annualized Factor / Market Cap
=- (0 + 0 + 0) * 4 / 9.586046
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PhaseRx Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.


PhaseRx Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of PhaseRx's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


PhaseRx (PhaseRx) Business Description

Traded in Other Exchanges
N/A
Address
410 West Harrison Street, Suite 300, Seattle, WA, USA, 98119
PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.
Executives
Gordon Brandt officer: Chief Medical Officer 410 WEST HARRISON STREET, SEATTLE WA 98119
Paul H Johnson director 3450 MONTE VILLA PARKWAY, BOTHELL WA 98053
Peggy V Phillips director C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Michelle Renee Griffin director 19723 NE 65TH LANE, KIRKLAND WA 98033
Brian G Atwood director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Schmidt John A Jr director 300 THIRD ST, CAMBRIDGE X1 02142
Steven Gillis director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Samuel D Colella 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Robert Nelsen 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Rebecca B Robertson 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Barbara N Lubash 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Donald B Milder 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Charles M Warden 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Venture Capital Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104

PhaseRx (PhaseRx) Headlines

From GuruFocus

PhaseRX: The Latest Pick From a Legendary VC Firm

By $$$ Christopher Malcolm 05-24-2016

Stocks Open Higher in Friday Session

By Omar Venerio Omar Venerio 10-13-2017